Kevin HealySenior Vice President, Regulatory Affairs, Pharmacovigilance, and Quality at Enzyvant
Kevin Healy, PhD, RAC
Kevin Healy is Enzyvant’s Senior Vice President, Regulatory Affairs, Pharmacovigilance, and Quality. In this role, Kevin had primary responsibility for guiding RETHYMIC®, designated as a Regenerative Medicine Advanced Therapy (RMAT), to an FDA approval in 2021. Kevin has over 15 years of biotech and pharmaceutical experience, and has been instrumental in advancing the development and approval of multiple therapies at Gilead Sciences, Mallinckrodt Pharmaceuticals, and Roivant Sciences.
Kevin received his BS in Biological Sciences from Cornell University, his PhD in Biochemistry from the University of Wisconsin–Madison, and completed a postdoctoral research fellowship at the University of North Carolina at Chapel Hill.